Publications

Researched and Curated by Clinical and Scientific Experts.

Every Hayes clinical evidence report is developed by experienced teams that have been trusted by healthcare decision makers since 1989. Here is a sampling of our content that is being used every day to inform defensible, evidence-based decisions by payers and providers.

Not all reports are available for public preview. For more information, please contact us.

Relyvrio (Sodium Phenylbutyrate/Taurursodiol) for Amyotrophic Lateral Sclerosis (ALS)

Relyvrio (formerly AMX0035) is an oral fixed-dose combination of sodium phenylbutyrate (PB) and taurursodiol (TURSO). PB is a prescription drug used to treat urea cycle disorders and TURSO (also known as tauroursodeoxycholic acid [TUDCA]) is a widely available non-prescription supplement. Relyvrio is indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults…

read more

Etranacogene Dezaparvovec for Hemophilia B

Etranacogene dezaparvovec (formerly AMT-061) is an investigational recombinant gene transfer therapy product designed to help patients with hemophilia B produce sufficient plasma levels of endogenous coagulation factor IX (FIX). The main therapeutic goal is long-term expression of FIX at levels steady enough to eliminate the need for routine prophylactic replacement therapy w…

read more